Table 5.
Univariable and multivariable analyses of prognostic factors for infectious episode in the first four cycles (N = 412 patients, 308 infectious events).
| Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|
| Infection | No infection | p | OR [95% CI] | p | |
| Age (median, IQR) | 77 (69–784) | 77 (69–78) | 0.28 | ||
| Sex, N (%) | |||||
| Male | 176/835 (21) | 659/835 (79) | 0.82 | ||
| Female | 132/608 (22) | 476/608 (78) | |||
| ⩾20% BM blasts | |||||
| Yes | 65/209 (31) | 144/209 (69) | <0.001 | 1.57 a (1.19–2.01) | <0.001 |
| No | 239/1222 (20) | 983/1222 (80) | |||
| Cytogenetic risk | |||||
| Good/intermediate | 155/900 (17) | 745/900 (83) | <0.0001 | 1.7 (1.35–2.14) | 0.001 |
| Unfavorable | 146/514 (28) | 368/514 (72) | |||
| NA | 7/29 (24) | 22/29 (76) | |||
| Hemoglobin (g/dl) | 9 (8.2–9.7) | 9.5 (8.5–10.6) | <0.0001 | 0.65 (0.51–0.82) b | <0.001 |
| Platelet count (×109/l) | 53 (25–109) | 76 (34–143) | <0.0001 | 0.997 (0.996–0.998) | 0.01 |
| IPSS-R (MDS patients) | |||||
| <3.5 | 1/12 (8) | 11/12 (92) | 0.37 | ||
| 3.5–4.5 | 45/265 (17) | 220/265 (83) | |||
| >4.5 | 174/829 (21) | 655/829 (79) | |||
| NA | 6/27 (22) | 21/27 (78) | |||
| Type of HMA | |||||
| Azacitidine | 288/1352 (21) | 1064/1352 (79) | 0.98 | ||
| Decitabine | 20/91 (20) | 71/91 (106) | |||
| ANC | 0.66 (0.24–1.8) | 1.00 (0.49–2.18) | <0.0001 | 0.98 (0.95–1.01) | 0.3 |
| ANC <0.5 × 109/l | |||||
| Without FQ | 78/225 (35) | 147/225 (65) | 0.03 | 1.62 (1.12–2.34) | 0.01 |
| With FQ | 44/180 (24) | 136/180 (76) | |||
AML, acute myeloid leukemia; ANC, absolute neutrophil counts; BM, bone marrow; CMML, chronic myelomonocytic leukemia; FQ, fluoroquinolone; Hb, hemoglobin; HMA, hypomethylating agent; IPSS-R, International Prognostic Score System–Revised; MDS, myelodysplastic syndrome; WHO, World Health Organization.
a
Cutoff value of 20%.
b
Cutoff value of 9 g/dl.